NCT03147196View on ClinicalTrials.gov

Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 27, 2017

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Stage I Prostate AdenocarcinomaStage II Prostate Adenocarcinoma
Interventions
DRUG

Bicalutamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Raloxifene Hydrochloride

Given PO

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT03147196 - Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Biotech Hunter | Biotech Hunter